• Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock
Investing

Moderna posts surprise profit as COVID vaccine sales exceed expectations

by November 7, 2024
written by November 7, 2024

Moderna reported a surprising third-quarter profit on Thursday, driven by cost reductions and stronger-than-expected sales of its COVID-19 vaccine, despite lower-than-anticipated revenue from its new respiratory syncytial virus (RSV) vaccine.

Shares of the Cambridge, Massachusetts-based company jumped 11% in premarket trading.

For the quarter, Moderna posted a profit of $13 million, or 3 cents per share, compared to a loss of $3.6 billion in the same period last year.

Analysts had expected a loss of $753 million, or $1.90 per share, according to LSEG data, Reuters reported.

Sales of its Spikevax COVID vaccine reached $1.8 billion, up 3.5% year-over-year, surpassing analysts’ expectations of $1.38 billion.

The company attributed this strong performance to increased sales in the US following an early launch of the vaccine this year.

The US Food and Drug Administration approved updated versions of Spikevax and Pfizer’s Comirnaty nearly three weeks earlier than in 2023.

Moderna noted that international sales of Spikevax were lower compared to the same period in 2023 when sales were boosted by deferred orders from 2022.

Operating expenses for the quarter totaled $1.93 billion, nearly 50% lower than the previous year, largely due to reduced unused manufacturing capacity and fewer inventory write-downs.

RSV vaccine, mRESVIA, generate $10 million in sales

The company’s new RSV vaccine, mRESVIA, generated $10 million in sales, falling significantly short of the $135 million analysts had expected. Despite this, Moderna reaffirmed its annual sales forecast of $3 billion to $3.5 billion.

“This guidance looks well within reach, especially with strong expected sales in Q4 from the COVID vaccine,” said TD Cowen analyst Tyler Van Buren.

Moderna is increasingly relying on revenue from newer mRNA vaccines, such as mRESVIA and an experimental COVID-19 combination vaccine, to offset declining demand for COVID-19 products post-pandemic.

Mock explained that the company struggled to compete during the peak of the RSV contracting season because mRESVIA was approved later in the year, and many contracts and inventory had already been secured.

US market share for Spikevax fell to 40%, down from 45% in Q3 2023. Moderna reported that 7.5 million patients received Spikevax this year, compared to nearly 11 million people who received Pfizer’s COVID-19 vaccine during the same period, according to IQVIA data.

The post Moderna posts surprise profit as COVID vaccine sales exceed expectations appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Israel takes hard line against terrorists, allowing deportation of family members
next post
Why ON Semiconductor is a strong buy despite recent market challenges

related articles

Asian markets open: Nikkei, Hang Seng fall on...

June 12, 2025

Aluminum and steel tariffs spark rise in secondary...

June 12, 2025

Airbus sees aviation boom ahead, global fleet to...

June 12, 2025

US-China trade talks and Washington’s decade-long effort to...

June 12, 2025

Europe markets open: Stoxx 600 dips as UK...

June 12, 2025

UK GDP falls by 0.3% in April as...

June 12, 2025

Gordon Brothers buys Poundland; pledges £80 mn for...

June 12, 2025

Air India plane crash: London-bound flight with 242...

June 12, 2025

Air India plane crash live update: Indian President...

June 12, 2025

Copper remains supported for now even as China...

June 12, 2025
Enter Your Information Below To Receive Free Trading Ideas, Latest News, And Articles.


Your information is secure and your privacy is protected. By opting in you agree to receive emails from us. Remember that you can opt-out any time, we hate spam too!

Latest News

  • Alina Habba accuses Kamala Harris of ‘committing a crime,’ covering up Biden’s health

    August 1, 2024
  • House Republicans face mounting resistance as third ex-Biden WH aide pleads Fifth Amendment

    July 18, 2025
  • Trump warns of ‘serious consequences’ if Elon Musk funds Democrats

    June 7, 2025
  • Biden, Harris call for Supreme Court term limits, code of conduct, limits on presidential immunity

    July 29, 2024
  • Trump to formally accept Republican presidential nomination in speech altered after assassination attempt

    July 18, 2024

Popular Posts

  • 1

    Secret Service admits leaning on ‘state and local partners’ after claim it ignored Trump team’s past requests

    July 21, 2024
  • 2

    Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024
  • 3

    Forex Profit Calculator: Maximize Your Trading Potential

    July 10, 2024
  • 4

    Elon and Vivek should tackle US funding for this boondoogle organization and score a multimillion dollar win

    December 4, 2024
  • 5

    Biden calls to ‘lower the temperature’ then bashes Trump in NAACP speech

    July 17, 2024

Categories

  • Economy (829)
  • Editor's Pick (6,509)
  • Investing (634)
  • Stock (941)

Latest Posts

  • Iran remembers Hamas leader Yahya Sinwar as a ‘martyr’ and ‘model for the youth and children’

    October 18, 2024
  • Biden admits keeping classified Afghanistan document ‘for posterity’s sake’ in leaked audio

    May 17, 2025
  • Five more House Democrats call on Biden to drop out, third US senator

    July 19, 2024

Recent Posts

  • AG Pam Bondi says FBI delivered ‘truckload’ of Epstein files after she put out hard deadline

    March 4, 2025
  • Biden WH adviser dodges whether he’s concerned Trump FBI pick labeled him ‘deep state’ member

    December 1, 2024
  • ‘Schumer shutdown’ already cost taxpayers $1.2B in pay to employees not working

    October 4, 2025

Editor’s Pick

  • Potential 2028 hopeful accused of ‘inciting violence’ after call for ‘mass protests’ against Trump

    April 29, 2025
  • DirecTV is pushing its pay TV bundle — without a satellite dish

    August 13, 2024
  • Trump pushes tax hikes for wealthy as ‘big, beautiful bill’ deadline looms

    May 9, 2025
  • About us
  • Contacts
  • Privacy Policy
  • Terms & Conditions

Disclaimer: moneyrisetoday.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2025 moneyrisetoday.com | All Rights Reserved

Money Rise Today – Investing and Stock News
  • Economy
  • Editor’s Pick
Money Rise Today – Investing and Stock News
  • Investing
  • Stock